MYmAb Biologics
Research & Development

In tumour tissue, the occurrence of aberrant glycosylation leads to the overexpression of tumour-associated glycans. Many of these aberrantly expressed tumour-associated glycans have been shown to correlate with the poor prognosis and survival of cancer patients. Hence, they are a class of attractive antigens for the development of anti-cancer immunotherapy. However, due to their low immunogenicity, glycans have been proven to be difficult to induce a high-affinity IgG antibody response. In addition, their complex structures often induce non-specific antibody responses. 

At MYmAb Biologics, we leverage an experienced scientific team to develop a new antibody technology platform, called GlykoGuard™. We are a group of committed scientists aims to generate highly specific, high-affinity IgG anti-glycan monoclonal antibodies to a broad range of tumour associated glycan antigens overexpressed in tumour tissues. We are excited about the potential of GlykoGuard™ to generate high-quality anti-glycan monoclonal antibodies that can be used in therapy, diagnosis and research. What drives us all at MYmAb Biologics is the desire to improve patients’ health and to help patients live longer.